Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$437.46+0.87(+0.20%)Visa Releases First-of-Its-Kind Industry Benchmark for AI Shopping; Almost Half of Test Runs Fail9:43:00 AM ETCAT$576.78-14.32(-2.42%)Demolition Tools Market - Global Forecast 2026-2032 | Market to Reach USD 4.81 Billion as Battery Power, AI, and Circular Construction Drive Growth9:36:39 AM ETARM$173.20-19.08(-9.92%)Arm Just Shipped 10 Billion Chips in a Single Quarter for the First Time9:31:16 AM ETAVGO$309.72-15.98(-4.91%)Power Semiconductor Module Market - Global Forecast 2026-2032 | Electrification, AI Data Centers, and Wide-Bandgap Adoption Drive 7.68% CAGR Toward USD 76.66 Billion9:30:42 AM ETPLTR$158.84-12.90(-7.51%)Is Palantir Stock a Buy on the Dip as Revenue Continues to Surge?9:30:00 AM ETTMO$695.96-10.07(-1.43%)AI in Genomics Market Size, Share, Growth, and Competitive Analysis - Global Forecast 2026-2035 | 32.40% CAGR to USD 14.55 Billion as Precision Medicine and Drug Discovery Scale9:27:39 AM ETC$125.45+0.68(+0.55%)UPDATE 7-Oil rises as investors weigh uncertainties around Iran war9:25:37 AM ETAMZN$266.51+0.32(+0.12%)Global Delivery Drones Market by Payload, Range, MTOW, Platform, Application, and Region - Forecast to 2031 | Healthcare and Hybrid Drones Fuel 21.6% CAGR to $7.65 Billion9:23:39 AM ETRDW$6.92-0.79(-10.25%)BUZZ-US STOCKS ON THE MOVE-ConocoPhillips, Sezzle, Cardinal Health9:20:53 AM ETAMD$436.41-52.28(-10.70%)Heterogeneous Computing Market Size and Share - Industry Trends and Growth Forecasts (2026-2031) | Generative AI and Cloud Adoption Fuel 21.87% CAGR9:20:42 AM ETCOHR$179.60-15.62(-8.00%)Coherent Now Sees Growth Above 60% and Its First $4 Billion Quarter by Fiscal 20289:19:53 AM ETXOM$172.30+2.90(+1.71%)Liz Ann Sonders Says "Rotation Is the New Momentum Trade." Here’s Where Money Could Move Next9:19:49 AM ETAMD$436.41-52.28(-10.70%)Global Accelerated Computing Market Size, Share, Industry Trends, and Growth Forecasts, 2026-2031 | AI Training and Edge Inference Fuel 20.19% CAGR and Custom Silicon Opportunities9:19:40 AM ETFISI$41.32+0.86(+2.13%)Virtual Desktop Infrastructure (VDI) Endpoint Market Size, Share, Trends, and Forecast 2026-2031 | Hybrid Work and Zero Trust Drive 14.48% CAGR Toward USD 9.89 Billion9:18:45 AM ETMSFT$548.38-7.63(-1.37%)Carbon-Aware Computing Platform Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI Demand and ESG Mandates Propel Market to USD 2.95 Billion9:17:39 AM ETSOLV$89.47+0.12(+0.13%)UAE Hospital Supplies Market Size and Share Analysis, Industry Trends, and Growth Forecasts, 2026-2031 | AI Procurement and Infection-Control Demand Fuel 8.10% CAGR9:11:38 AM ETACN$266.32+1.91(+0.72%)Application Outsourcing - Market Size, Share, Industry Trends, and Growth Forecasts, 2026-2031 | Cloud, AI, and Security Demand Drive Market to USD 215.46 Billion9:10:49 AM ETCSCO$100.98-2.68(-2.59%)Desktop Virtualization Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | Cloud DaaS and Hybrid Work Propel Market to USD 20.54 Billion as Asia-Pacific Leads Growth9:09:39 AM ETIBM$252.00-2.32(-0.91%)Industrial Edge Computing Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | Edge AI, IIoT, and Private-5G Drive 13.24% CAGR to USD 114.87 Billion9:08:39 AM ETQUBT$5.95-0.48(-7.47%)Next-generation Computing Market Size, Share, Trends, and Growth Forecasts 2026-2031 | AI, Quantum, and Edge Investment Drive 19.02% CAGR to USD 650.48 Billion9:07:40 AM ETDIS$119.88+0.90(+0.76%)I've Been Writing About Disney Stock for 30 Years. Here's Why My Conviction Has Never Been Higher.9:07:00 AM ETAAPL$351.49+1.93(+0.55%)Stock Market Today: Rotation Away From AI Stocks Increases as Money Flows to AI Landlords9:06:48 AM ETKO$96.04+0.16(+0.17%)Digital Transformation (DX) - Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI and Cloud Adoption Drive Growth to USD 5.33 Trillion9:05:41 AM ETMSFT$548.38-7.63(-1.37%)Not One Analyst Rates Microsoft a Sell. Is the Consensus View Right?9:05:39 AM ET

KAPA · AMEX

Kairos Pharma, Ltd.

$0.52 +0.03 (+6.12%)

Company overview

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Market cap
$1.8M
Employees
1
Headquarters
Los Angeles, CA
Website
kairospharma.com
CEO
John S. Yu
Listed
September 16, 2024
P/E
-1.64
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$80,000
Operating income
-$6.1M
EBITDA
-$5.6M
Net income
-$5.8M
EPS
-$0.30
Total assets
$5.7M
Total debt
$0.00
Earnings yield
-61.06%

Price chart

0.271.272.273.284.28
KAPA 1D AMEX O0.51H0.53L0.49C0.49-0.02 (-3.03%)Vol40.10K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development Business Wire
KAPAKairos Pharma, Ltd. Press release CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma Newsfile
KAPAKairos Pharma, Ltd. Stock news Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer Benzinga
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Announces 1-for-7 Reverse Stock Split Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer Business Wire
JBHT Stock news Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket Benzinga
KAPAKairos Pharma, Ltd. Press release CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever Newsfile Corp
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award Business Wire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI Newsfile Corp
KAPAKairos Pharma, Ltd. Press release Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings Business Wire
KAPAKairos Pharma, Ltd. Legal KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm GlobeNewswire
KAPAKairos Pharma, Ltd. Press release Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation Business Wire
KAPAKairos Pharma, Ltd. Legal Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA Business Wire
See more
FAQ

Questions about Kairos Pharma, Ltd.

What does Kairos Pharma, Ltd. do?
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
What is KAPA's market cap?
Kairos Pharma, Ltd. (KAPA) is a listed stock with a live quote. The latest market cap on this page is $1.8M.
Where is Kairos Pharma, Ltd. headquartered?
Kairos Pharma, Ltd. is headquartered in Los Angeles, CA.
How do I get KAPA news from the API?
Call GET /v1/news?tickers=KAPA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does KAPA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for KAPA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the KAPA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs